Targets › LOXL2
2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Immunology, Respiratory, Oncology; next expected readout Jun 2027.
Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. (UniProt, Q9Y4K0)
Open in Phaseline: the race on LOXL2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | BMS-986278 LOXL2 inhibitor | LOXL2 | Phase 3 | Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis | Jun 2027 |
| Galecto Biotech | GB2064 LOXL2 inhibitor | LOXL2 | Phase 2 | Myelofibrosis | – |
Idiopathic Pulmonary Fibrosis (1) Progressive Pulmonary Fibrosis (1) Myelofibrosis (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.